## Mars (Mars Fishcare)

Chemwatch Hazard Alert C

Chemwatch: 4650-20 Version No: 6.1.1. Safety Data Sheet according to OSHA HazCom Standard (2012) requirements Issue Date: **10/31/2017** Print Date: **11/01/2017** L.GHS.USA.EN

## SECTION 1 IDENTIFICATION

#### **Product Identifier**

Product name	Liquid Nitrate Test Solution #2
Synonyms	Solution ID# 3307
Other means of identification	Not Available

## Recommended use of the chemical and restrictions on use

Relevant identified uses	Nitrate test solution for product LR1800, 34 and 401M.
--------------------------	--

## Name, address, and telephone number of the chemical manufacturer, importer, or other responsible party

Registered company name	Mars (Mars Fishcare)
Address	3250 East 44th Street Vernon California 90058 United States
Telephone	+1 213 587 2727
Fax	+1 213 586 8347
Website	Not Available
Email	Not Available

## **Emergency phone number**

Association / Organisation	Not Available
Emergency telephone numbers	Not Available
Other emergency telephone numbers	Not Available

### **SECTION 2 HAZARD(S) IDENTIFICATION**

## Classification of the substance or mixture

NFPA 704 diamond



Note: The hazard category numbers found in GHS classification in section 2 of this SDSs are NOT to be used to fill in the NFPA 704 diamond. Blue = Health Red = Fire Yellow = Reactivity White = Special (Oxidizer or water reactive substances)

Classification Eye Irritation Category 2B

## Label elements

Hazard pictogram(s)	Not Applicable
SIGNAL WORD	WARNING
Hazard statement(s)	
H320	Causes eye irritation.

## Hazard(s) not otherwise specified

Not Applicable

#### Precautionary statement(s) Prevention

P264	Wash all exposed external body areas thoroughly after handling.
------	---

#### Precautionary statement(s) Response

P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337+P313	If eye irritation persists: Get medical advice/attention.

#### Precautionary statement(s) Storage

Not Applicable

#### Precautionary statement(s) Disposal

Not Applicable

#### SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

#### Substances

See section below for composition of Mixtures

#### **Mixtures**

CAS No	%[weight]	Name
25322-68-3	98	polyethylene glycol
63-74-1	<5	sulfanilamide

## **SECTION 4 FIRST-AID MEASURES**

#### Description of first aid measures If this product comes in contact with the eyes: Wash out immediately with fresh running water. • Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by **Eve Contact** occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. ▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Skin Contact Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. + If fumes, aerosols or combustion products are inhaled remove from contaminated area. Inhalation Other measures are usually unnecessary. Immediately give a glass of water. Ingestion First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.

## Most important symptoms and effects, both acute and delayed

See Section 11

#### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

In cases of recent sulfonamide overdose the stomach should be emptied by aspiration and lavage. If kidney function is adequate, a saline purgative, such as sodium sulfate, 30 g in 250 ml water, may be given to promote peristalsis and elimination of sulfonamide in the urine may be assisted by giving alkalies, such as sodium bicarbonate and increasing fluid intake. Severe crystalluria may require ureteric catheterisation and irrigation with warm 2.5% sodium bicarbonate solution. Treatment should be continued until it can be assumed that the sulfonamide has been eliminated. The majority of sulfonamides are metabolised to acetylated derivatives which retain the toxicity of the parent compound and thus may indicate more active removal when adverse effects are very severe. Active measures may include forced diuresis, peritoneal dialysis and charcoal haemoperfusion.

[Martindale: The Extra Pharmacopoeia, 28th Ed.]

## Extinguishing media

- Water spray or fog.
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.

## Special hazards arising from the substrate or mixture

Fire Incompatibility	<ul> <li>Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result</li> </ul>
----------------------	--

## Special protective equipment and precautions for fire-fighters

Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear full body protective clothing with breathing apparatus.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>Use water delivered as a fine spray to control fire and cool adjacent area.</li> <li>Avoid spraying water onto liquid pools.</li> <li><b>DO NOT</b> approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> </ul>
Fire/Explosion Hazard	<ul> <li>Combustible.</li> <li>Slight fire hazard when exposed to heat or flame.</li> <li>Heating may cause expansion or decomposition leading to violent rupture of containers.</li> <li>On combustion, may emit toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> <li>Mists containing combustible materials may be explosive.</li> <li>Combustion products include: </li> <li>, carbon dioxide (CO2) </li> <li>, nitrogen oxides (NOx) </li> <li>, other pyrolysis products typical of burning organic material.</li> <li>May emit corrosive fumes.</li> </ul>

## SECTION 6 ACCIDENTAL RELEASE MEASURES

## Personal precautions, protective equipment and emergency procedures

See section 8

## **Environmental precautions**

See section 12

## Methods and material for containment and cleaning up

Minor Spills	<ul> <li>Remove all ignition sources.</li> <li>Clean up all spills immediately.</li> <li>Avoid breathing vapours and contact with skin and eyes.</li> <li>Control personal contact with the substance, by using protective equipment.</li> <li>Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>Wipe up.</li> <li>Place in a suitable, labelled container for waste disposal.</li> </ul>
Major Spills	<ul> <li>Moderate hazard.</li> <li>Clear area of personnel and move upwind.</li> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Increase ventilation.</li> <li>Stop leak if safe to do so.</li> <li>Contain spill with sand, earth or vermiculite.</li> <li>Collect recoverable product into labelled containers for recycling.</li> <li>Absorb remaining product with sand, earth or vermiculite.</li> <li>Collect solid residues and seal in labelled drums for disposal.</li> <li>Wash area and prevent runoff into drains.</li> </ul>

• If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

## SECTION 7 HANDLING AND STORAGE

#### Precautions for safe handling

Safe handling	<ul> <li>DO NOT USE brass or copper containers / stirrers</li> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>Avoid smoking, naked lights or ignition sources.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.</li> </ul>
Other information	<ul> <li>Store in original containers.</li> <li>Keep containers securely sealed.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Store in a cool, dry, well-ventilated area.</li> <li>Store away from incompatible materials and foodstuff containers.</li> <li>Protect containers against physical damage and check regularly for leaks.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

## Conditions for safe storage, including any incompatibilities

Suitable container	<ul> <li>Metal can or drum</li> <li>Packaging as recommended by manufacturer.</li> <li>Check all containers are clearly labelled and free from leaks.</li> </ul>
Storage incompatibility	Avoid reaction with oxidising agents

## SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

## **Control parameters**

### OCCUPATIONAL EXPOSURE LIMITS (OEL)

#### INGREDIENT DATA

Not Available

#### EMERGENCY LIMITS

Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
polyethylene glycol	Polyethylene glycol	30 mg/m3	1,300 mg/m3	7,700 mg/m3
sulfanilamide	Sulfanilamide	13 mg/m3	140 mg/m3	830 mg/m3
Ingredient	Original IDLH		Revised IDLH	
polyethylene glycol	Not Available		Not Available	
sulfanilamide	Not Available		Not Available	

MATERIAL DATA

#### **Exposure controls**

Appropriate engineering controls
-------------------------------------

	ventilation that strategically "adds" and "removes" air in the work environment contaminant if designed properly. The design of a ventilation system must ma contaminant in use. Employers may need to use multiple types of controls to prevent employee of	atch the particular proce		
	General exhaust is adequate under normal operating conditions. Local exhaust circumstances. If risk of overexposure exists, wear approved respirator. Supp special circumstances. Correct fit is essential to ensure adequate protection. and enclosed storage areas. Air contaminants generated in the workplace pos- turn, determine the "capture velocities" of fresh circulating air required to effort	blied-air type respirator Provide adequate venti ssess varying "escape"	may be required in lation in warehouses velocities which, in	
	Type of Contaminant:		Air Speed:	
	solvent, vapours, degreasing etc., evaporating from tank (in still air).		0.25-0.5 m/s (50-100 f/min)	
	aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)			
	direct spray, spray painting in shallow booths, drum filling, conveyer loading discharge (active generation into zone of rapid air motion)	, crusher dusts, gas	1-2.5 m/s (200-500 f/min.)	
	grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion)       2.5-10 m/s (500-2000 f/min.)         Within each range the appropriate value depends on:       2.5-10 m/s (500-2000 f/min.)			
	Lower end of the range	Upper end of the rang	ge	
	1: Room air currents minimal or favourable to capture	1: Disturbing room ail	r currents	
	2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of h	igh toxicity	
	3: Intermittent, low production.	3: High production, h	eavy use	
	4: Large hood or large air mass in motion	ontrol only		
	Simple theory shows that air velocity falls rapidly with distance away from the Velocity generally decreases with the square of distance from the extraction potent should be adjusted, accordingly, after reference. The air velocity at the extraction fan, for example, should be a minimum of 1 solvents generated in a tank 2 meters distant from the extraction point. Other performance deficits within the extraction apparatus, make it essential that the factors of 10 or more when extraction systems are installed or used.	boint (in simple cases). to distance from the co -2 m/s (200-400 f/min) mechanical considerat	Therefore the air ontaminating source. for extraction of ions, producing	
Personal protection				
Eye and face protection	<ul> <li>Safety glasses with side shields.</li> <li>Chemical goggles.</li> <li>Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]</li> </ul>			
Skin protection	See Hand protection below			
Hands/feet protection	<ul> <li>Wear chemical protective gloves, e.g. PVC.</li> <li>Wear safety footwear or safety gumboots, e.g. Rubber</li> </ul>			
Body protection	See Other protection below			

 Body protection
 See Other protection below

 Other protection

 Overalls.
 P.V.C. apron.
 Barrier cream.
 Skin cleansing cream.
 Eye wash unit.

 Thermal hazards
 Not Available

## **Respiratory protection**

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant.

Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1 P2	-
up to 50	1000	-	A-AUS / Class 1 P2
up to 50	5000	Airline *	-
up to 100	5000	-	A-2 P2
up to 100	10000	-	A-3 P2
100+			Airline**

\* - Continuous Flow \*\* - Continuous-flow or positive pressure demand

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

### SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

## Information on basic physical and chemical properties

Appearance	Translucent light gray liquid with no odour; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	1.127
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	Not Available	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water (g/L)	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

## SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	<ul> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

## SECTION 11 TOXICOLOGICAL INFORMATION

## Information on toxicological effects

information on toxicolog	
Inhaled	Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Not normally a hazard due to non-volatile nature of product
Ingestion	The material has <b>NOT</b> been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.
	<ul> <li>The material may produce mild skin irritation; limited evidence or practical experience suggests, that the material either:</li> <li>produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or</li> <li>produces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period.</li> </ul>
Skin Contact	Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (non allergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Limited evidence or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur. Ophthalmic solutions containing sulfonamides are reported to produce local irritation, reactive hyperaemia, burning and transient stinging, blurred vision and temporary impairment of depth perception. Hypersensitivity reactions may occur in predisposed individuals. Possible eye changes produced by phototoxic agents such as the sulfonamides include kerato-conjunctivitis or corneal and lens opacities.
Chronic	On the basis, primarily, of animal experiments, concern has been expressed by at least one classification body that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. There is some evidence to provide a presumption that human exposure to the material may result in impaired fertility on the basis of: some evidence in animal studies of impaired fertility in the absence of toxic effects, or evidence of impaired fertility in the absence of toxic effects. Exposure to the material may produce mutagenic effects. Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies with similar materials using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies. Repeated ingestion of sulfonamides used for therapeutic purposes has caused nausea, vomiting, abdominal pain, diarrhoea, anorexia, stomatitis, impaired folic acid absorption, exacerbation of porphyria, acidosis, liver injury with jaundice and hypoprothrombinemia, and pancreatitis. Hepatitis has been reported and may be fatal. Renal effects are often prominent and may include crystalluria, haematuria, proteinuria, pain and frequent urination, necrosis of the tubules, nephritic syndrome, and toxic necrosis with oliguria or anuria with azotenia. Neurologic effects include headache, drowsiness, insomnia, vertigo, tinnitus, hearing loss, mental depression, hallucinations, ataxia, muscular paralysis, peripheral neuropathy, transient lesions of the posterior spinal column, transverse myelitis, convulsions and unconsciousness. Haematological effects include eosinophilia, thrombocytopenia, lewkopenia, neutropenia, agranulocytosis, pancytopenia, megoblastic anaemia and cyanosis may also occur. Ocular effects may include acute transient myo

More severe responses to treatment include irreversible neuromuscular and central nervous system changes and fibrosing alveolitis. During sulfonamide treatment, direct exposure to sunlight should be avoided as photosensitisation dermatitis may develop. This form of phototoxic dermatitis may be contrasted to photoallergic dermatitis produced by specific sensitising agents through immunological intervention. Phototoxic reactions have been described following contact, ingestion or injection of causal agents. The chemical may reach the skin by the circulatory system following ingestion or following parenteral administration. The actual skin changes vary with the agent and circumstances of the exposure. Swelling and redness (erythema) frequently occur, and blistering may also result; increased skin temperature and pruritus may follow. This is analagous to irritant contact dermatitis and occurs immediately following contact.

Hyperpigmentation may also follow the reaction. Photodermatitis of this type requires activation of a chemical substance on the skin surface by UV radiation (290 to 490 nm wavelength) for its clinical expression. In all cases, inflammation develops on the body surfaces normally exposed to sunlight (dorsal hands, arms, neck, face), provided that the responsible photosensitiser also contacts the anatomic areas. Covered skin, the eyelids, submental chin and upper ears covered by hair, are characteristically spared. Phototoxic reactions, analogous to irritant contact dermatitis, are typically accompanied by immediate burning, stinging or "smarting" of the skin shortly following sun exposure, and clinical inflammation appears more like an acute sunburn than an eczematous dermatitis. Photoallergic dermatitis may result from contact with the material; this is characterised by an increased reactivity of the skin to ultra- violet (UV) and/or visible radiation produced by a chemical agent on an immunological basis and occurs after a latent period of days or months. This type of response can be elicited only in individuals who have been previously allergically sensitised to the chemical agent and appropriate radiation.

Photoallergic dermatitis is relatively rare (certainly more so than phototoxic dermatitis produced by non-immunological principals) and presents, clinically, as an eczematous dermatitis in sun-exposed areas (distinguishing it from phototoxic dermatitis which is analogous to contact irritant dermatitis and produces swelling, redness and even blistering); photoallergic dermatitis may eventually spread to areas covered by clothes. Lichenification (thickening with increased skin markings) and chronic pigmentary changes may also develop. Photoallergic reactions may sometimes be followed by a persistent state of light reactivity (persistent light reactor) where clinical dermatitis recurs following exposure to sunlight alone, in the absence of the original initiating chemical. Studies in rats have shown that long-term administration of sulfonamides may produce thyroid malignancies; rats, however, appear to be more susceptible to the goiterogenic effects of sulfonamides than do other animal species. Sulfonamides may cause kernicterus in the neonate and their use is not recommended during pregnancy. Studies in rats and mice given high oral doses have shown that certain sulfonamides cause a significant incidence of cleft palate and other bony abnormalities in the foetus.

Liquid Nitrate Test	TOXICITY	IRRITATION	
Solution #2	Not Available	Not Available	
	тохісітү	IRRITATION	
polyethylene glycol	Dermal (rabbit) LD50: >20000 mg/kg <sup>[2]</sup>	Eye (rabbit): 500mg/24h - mild.	
	Oral (rat) LD50: 600 mg/kg <sup>[2]</sup>	Skin (rabbit): 500mg/24h - mild.	
	TOXICITY	IRRITATION	
sulfanilamide	Oral (rat) LD50: 3900 mg/kg <sup>[2]</sup>	Not Available	
Legend:	<ol> <li>Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS.</li> <li>Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances</li> </ol>		

POLYETHYLENE GLYCOL	for polyethylene glycols Pure polyethylene glycols have essentially similar toxicity, with toxicity being inverse to molecular weights. Absorption from the gastrointestinal tract decreases with increasing molecular weight The G.I. absorption of a series of polyethylene glycols has been studied. Polyethylene glycols having average molecular weights of 4000 and 6000 showed no absorption from the rat intestine over a five-hour period, while polyethylene glycols of 1000 and 1540 molecular weights showed a slight absorption amounting to less than 2% of the total dose during the same period. When 1 g doses of polyethylene glycols of molecular weight 1000 (PEG 1000) and 6000 (PEG 6000) were given intravenously to six human subjects, 85% of PEG 1000 and 96% of PEG 6000 were excreted in the urine in 12 hours. When these two same materials in 10 g doses were given orally to five human subjects, none of the PEG 6000 was found in the urine in the following 24 hours, whereas about 8% of PEG 1000 administered was found to excrete in urine within 24 hours. When PEG 400 was given intravenously to three human subjects, an average of 77% recovery of this material was found in the urine in 12 hours. However, when the same substance was given orally to the same three human subjects, a recovery of between 40 and 50% of the dose was determined in the urine in the course of the following 24 hours. Single oral doses of PEG 400 were incompletely recovered from urine and faeces of rabbits even when collection of excreta was continued as long as four days following the dose. Evidence from all these and other studies indicate that ethylene glycol is not formed as a metabolite of PEG 400 Prolonged skin contact of PEG 1500 and 4000 upon the skin of rabbits in dosages of 10 g/kg bw showed no deleterious effects on internal organs and little, if any, of the materials was absorbed through the skin.
	indicate that ethylene glycol is not formed as a metabolite of PEG 400 Prolonged skin contact of PEG 1500 and 4000 upon the skin of rabbits in dosages of 10 g/kg bw showed no deleterious

	lower molecular weight liquid polyethylene glyd 400. Two other patients had delayed allergic e Polyethers, for example, ethoxylated surfacta the ether oxygens will stabilize intermediary (pentaethylene glycol mono-n-dodecyl ether) products when exposed to air. Sensitization studies in guinea pigs revealed to the investigated oxidation products are sensiti one (16-hydroperoxy-3,6,9,12,15-pentaoxaher sensitizer in LLNA (local lymph node assay for was indicated by the detection of their corresp On the basis of the lower irritancy, nonionic su However, their susceptibility towards autoxidation als to diagnose ACD to these compounds by pate Allergic Contact Dermatitis—Formation, Struc Ann-Therese Karlberg et al; Chem. Res. Toxic The material may be irritating to the eye, with irritants may produce conjunctivitis. The material may cause skin irritation after pro (nonallergic). This form of dermatitis is often of Histologically there may be intercellular oeder epidermis.	czematous reactions, one to PE nts and polyethylene glycols, a r radicals involved. Investigatic ethoxylate, showed that polyeth that the pure nonoxidized surfac zers. Two hydroperoxides were bacosan-1-ol ) was stable enou or detection of sensitization cap bonding aldehydes in the oxidati urfactants are often preferred to co increases the irritation. Bec ch testing. ctural Requirements, and Reacti ol.2008,21,53-69 prolonged or repeated exposure a characterised by skin redness (e	G 200, and one to PEG 300. re highly susceptible towards air oxidation as ons of a chemically well-defined alcohol hers form complex mixtures of oxidation that itself is nonsensitizing but that many of identified in the oxidation mixture, but only ugh to be isolated. It was found to be a strong acity). The formation of other hydroperoxides on mixture . b ionic surfactants in topical products. ause of their irritating effect, it is difficult vity of Skin Sensitizers. mmation. Repeated or prolonged exposure to and may produce a contact dermatitis erythema) and swelling epidermis.
SULFANILAMIDE	for molecular weights (200-8000) * Oral (rat) LD50: 31000->50000 mg/kg Oral (mice) LD50: 38000->50000 mg/kg Oral (g.pig) LD50: 17000->50000 mg/kg Oral (rabbit) LD50: 14000->50000 mg/kg * AIHA WEEL Guides Intraperitoneal (mice) LD50: 3100-12900 mg/kg Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure to the irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production. No significant acute toxicological data identified in literature search.		
Acute Toxicity	$\otimes$	Carcinogenicity	$\otimes$
Skin Irritation/Corrosion	0	Reproductivity	0
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	0

	Exposure
As	spiration Hazard
Legend:	🗙 – Data availa

STOT - Repeated

1: 🔀 – Data available but does not fill the criteria for classification

< – Data available to make classification

 $\odot$ 

 $\bigcirc$ 

🚫 – Data Not Available to make classification

#### **SECTION 12 ECOLOGICAL INFORMATION**

 $\bigcirc$ 

 $\bigcirc$ 

**Respiratory or Skin** 

sensitisation

Mutagenicity

Liquid Nitrate Test Solution #2	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
	Not Available	Not Available	Not Available	Not Available	Not Availabl
polyethylene glycol	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURC
	LC50	96	Fish	>1000mg/L	4
sulfanilamide	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
	Not Available	Not Available	Not Available	Not Available	Not Available

Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity
Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) -
Bioconcentration Data 8. Vendor Data

#### DO NOT discharge into sewer or waterways.

#### Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
polyethylene glycol	LOW	LOW
sulfanilamide	HIGH	HIGH

#### **Bioaccumulative potential**

Ingredient	Bioaccumulation
polyethylene glycol	LOW (LogKOW = -1.1996)
sulfanilamide	LOW (LogKOW = -0.62)

#### Mobility in soil

Ingredient	Mobility
polyethylene glycol	HIGH (KOC = 1)
sulfanilamide	LOW (KOC = 40.23)

#### SECTION 13 DISPOSAL CONSIDERATIONS

#### Waste treatment methods

	<ul> <li>Containers may still present a chemical hazard/ danger when empty.</li> <li>Return to supplier for reuse/ recycling if possible.</li> </ul>
Product / Packaging	Otherwise:
disposal	• If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used
	to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
	Where possible retain label warnings and SDS and observe all notices pertaining to the product.

## **SECTION 14 TRANSPORT INFORMATION**

#### Labels Required

Marine Pollutant NO

## Land transport (DOT): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

#### Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

## Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

#### SECTION 15 REGULATORY INFORMATION

## Safety, health and environmental regulations / legislation specific for the substance or mixture

#### POLYETHYLENE GLYCOL(25322-68-3) IS FOUND ON THE FOLLOWING REGULATORY LISTS

US AIHA Workplace Environmental Exposure Levels (WEELs) US List of Active Substances Exempt from the TSCA Inventory Notifications (Active-Inactive) Rule US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory US TSCA Chemical Substance Inventory - Interim List of Active Substances

#### SULFANILAMIDE(63-74-1) IS FOUND ON THE FOLLOWING REGULATORY LISTS

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

#### **Federal Regulations**

## Superfund Amendments and Reauthorization Act of 1986 (SARA)

## SECTION 311/312 HAZARD CATEGORIES

Immediate (acute) health hazard	Yes
Delayed (chronic) health hazard	No
Fire hazard	No
Pressure hazard	No
Reactivity hazard	No

## US. EPA CERCLA HAZARDOUS SUBSTANCES AND REPORTABLE QUANTITIES (40 CFR 302.4) None Reported

#### **State Regulations**

#### US. CALIFORNIA PROPOSITION 65

None Reported

National Inventory	Status
Australia - AICS	Y
Canada - DSL	Y
Canada - NDSL	N (polyethylene glycol; sulfanilamide)
China - IECSC	Y
Europe - EINEC / ELINCS / NLP	Υ
Japan - ENCS	Y
Korea - KECI	Y
New Zealand - NZIoC	Y
Philippines - PICCS	Y
USA - TSCA	Y
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

## **SECTION 16 OTHER INFORMATION**

## Other information

## Ingredients with multiple cas numbers

Name	CAS No
polyethylene glycol	25322-68-3, 8038-37-7, 9081-95-2, 9085-02-3, 9085-03-4, 12676-74-3, 12770-93-3, 25104-58-9, 25609-81-8, 34802-42-1, 37361-15-2, 50809-04-6, 50809-59-1, 54510-95-1, 54847-64-2, 59763-40-5, 60894-12-4, 61840-14-0, 64441-68-5, 64640-28-4, 67411-64-7, 70926-57-7, 75285-02-8, 75285-03-9, 77986-38-0, 79964-26-4, 80341-53-3, 85399-22-0, 85945-29-5, 88077-80-9, 88747-22-2, 90597-70-9, 99264-61-6, 99333-89-8, 101677-86-5, 106186-24-7, 107502-63-6, 107529-96-4, 109550-27-8, 112384-37-9, 112895-21-3, 114323-93-2, 116549-90-7, 119219-06-6, 125223-68-9, 133573-31-6, 134919-43-0, 150872-82-5, 154394-38-4, 156948-19-5, 169046-53-1, 174460-08-3, 174460-09-4, 188364-77-4, 188924-03-0, 189154-62-9, 191743-71-2, 196696-84-1, 201163-43-1, 206357-86-0

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### **Definitions and abbreviations**

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit。

IDLH: Immediately Dangerous to Life or Health Concentrations

OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

